{"id":745531,"date":"2017-06-05T06:30:00","date_gmt":"2017-06-05T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/"},"modified":"2025-11-07T01:26:25","modified_gmt":"2025-11-07T06:26:25","slug":"updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/","title":{"rendered":"Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1"},"content":{"rendered":"<p class=\"bwalignc\">       Longer-Term Findings to Be Presented at 2017 ASCO Annual Meeting     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced updated overall survival (OS) findings from KEYNOTE-024,<br \/>\n      the phase 3 study evaluating KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the<br \/>\n      company\u2019s anti-PD-1 therapy, as a monotherapy compared to<br \/>\n      platinum-containing chemotherapy in the first-line treatment of patients<br \/>\n      with advanced non-small cell lung cancer (NSCLC) whose tumors express<br \/>\n      high levels of PD-L1 (tumor proportion score [TPS] of 50 percent or<br \/>\n      more). The study included patients with squamous and non-squamous NSCLC<br \/>\n      with no EGFR or ALK genomic tumor aberrations and demonstrated a<br \/>\n      reduction in the risk of death by 37 percent for KEYTRUDA compared to<br \/>\n      chemotherapy based on 19 months of median follow-up (HR, 0.63 [95% CI,<br \/>\n      0.46-0.88]; p = 0.003). Additionally, in an exploratory analysis,<br \/>\n      progression-free survival 2 (PFS2) \u2013 a clinical endpoint used to assess<br \/>\n      the impact of next-line treatment on disease control \u2013 was substantially<br \/>\n      improved for patients in the KEYTRUDA group compared to the chemotherapy<br \/>\n      group. These data are being presented in an oral session at the 2017<br \/>\n      American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago<br \/>\n      on Tuesday, June 6, from 9:45 \u2013 9:57 a.m. CDT (Location: Hall D1)<br \/>\n      (Abstract #9000).\n    <\/p>\n<p>\n      With approximately eight additional months of follow-up, data showed<br \/>\n      continued OS benefit with KEYTRUDA over chemotherapy in the first-line<br \/>\n      treatment of patients with advanced NSCLC whose tumors expressed high<br \/>\n      levels of PD-L1 \u2013 showing an 18-month OS rate of 61.2 percent in the<br \/>\n      KEYTRUDA group compared to 43.0 percent in the chemotherapy group; the<br \/>\n      12-month OS rate was 70.3 percent in the KEYTRUDA group compared to 54.8<br \/>\n      percent in the chemotherapy group.\n    <\/p>\n<p>\n      For PFS2, findings based on 19 months of median follow-up showed a 46<br \/>\n      percent reduction in the risk of progression after the start of the<br \/>\n      second-line regimen or death in patients initially randomized to<br \/>\n      KEYTRUDA compared to patients initially randomized to chemotherapy (HR,<br \/>\n      0.54 [95% CI, 0.40-0.72]; p &lt; 0.001]).\n    <\/p>\n<p>\n      \u201cFrom the start of the KEYTRUDA program in non-small cell lung cancer,<br \/>\n      one of our goals has been to demonstrate the value of KEYTRUDA<br \/>\n      monotherapy in appropriate patient populations,\u201d said Dr. Roger Dansey,<br \/>\n      senior vice president and therapeutic area head, oncology late-stage<br \/>\n      development, Merck Research Laboratories.&nbsp;\u201cWith updated data from<br \/>\n      KEYNOTE-024, as well as from other studies in our clinical development<br \/>\n      program, we are establishing the role of KEYTRUDA in the treatment of<br \/>\n      advanced non-small cell lung cancer.\u201d\n    <\/p>\n<p>\n      Merck has a robust clinical development program for KEYTRUDA in lung<br \/>\n      cancer, with multiple registration-enabling studies currently underway.<br \/>\n      The KEYTRUDA clinical development program includes more than 30 tumor<br \/>\n      types in more than 500 clinical trials, including more than 300 trials<br \/>\n      that combine KEYTRUDA with other cancer treatments.\n    <\/p>\n<p>\n      \u201cThese results from additional follow-up in KEYNOTE-024 \u2013 including<br \/>\n      improved overall survival despite significant crossover \u2013 give us<br \/>\n      further confidence in KEYTRUDA as a first-line treatment for patients<br \/>\n      with non-small cell lung cancer whose tumors express high levels of<br \/>\n      PD-L1,\u201d said Prof. Martin Reck, head of the department of thoracic<br \/>\n      oncology, LungenClinic Grosshansdorf, Germany.\n    <\/p>\n<p>\n      <b>Key Findings from the KEYNOTE-024 Study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-024 is a randomized, phase 3 study of 305 patients with<br \/>\n      metastatic NSCLC who were assigned either KEYTRUDA (pembrolizumab) as<br \/>\n      monotherapy (n=154) or standard of care platinum-based chemotherapy<br \/>\n      (n=151). Enrollment criteria included: having no prior systemic<br \/>\n      chemotherapy treatment for their advanced disease, tumors without an<br \/>\n      EGFR sensitizing mutation or ALK translocation, and tumors expressing<br \/>\n      high levels of PD-L1 (TPS of 50 percent or more) as determined by a<br \/>\n      central laboratory using the Dako PD-L1 IHC 22C3 PharmDx test, from<br \/>\n      Agilent Technologies. The primary endpoint was progression-free survival<br \/>\n      (PFS) and the key secondary endpoint was OS. Other secondary endpoints<br \/>\n      include overall response rate (ORR) and safety. Exploratory endpoints<br \/>\n      include PFS2 and duration of response.\n    <\/p>\n<p>\n      Data presented at ASCO are based on a median follow-up of 19.1 months<br \/>\n      (range: 14.3-27.6) and include findings from 79 patients who crossed<br \/>\n      over from the chemotherapy arm to receive KEYTRUDA, per study protocol,<br \/>\n      and 12 patients who received anti-PD-1 therapy outside of study<br \/>\n      crossover. Results show that KEYTRUDA maintained an OS benefit over<br \/>\n      chemotherapy in patients whose tumors expressed high levels of PD-L1<br \/>\n      (TPS of 50 percent or more), with a 37 percent reduction in the risk of<br \/>\n      death (HR, 0.63 [95% CI, 0.46-0.88]; p = 0.003). The 12-month OS rate<br \/>\n      was 70.3 percent in the KEYTRUDA group compared to 54.8 percent in the<br \/>\n      chemotherapy group; at 18 months, the OS rate was 61.2 percent in the<br \/>\n      KEYTRUDA group compared to 43.0 percent in the chemotherapy group. The<br \/>\n      median OS had not yet been reached in the KEYTRUDA group (95% CI,<br \/>\n      19.4-NE), compared to 14.5 months in the chemotherapy group (95% CI,<br \/>\n      9.8-19.6).\n    <\/p>\n<p>\n      In an exploratory analysis of PFS2 \u2013 a clinical endpoint used to assess<br \/>\n      the impact of next-line treatment on disease control \u2013 findings showed a<br \/>\n      46 percent reduction in the risk of progression after initiation of the<br \/>\n      second-line regimen or death in patients initially randomized to<br \/>\n      KEYTRUDA compared to patients initially randomized to chemotherapy (HR,<br \/>\n      0.54 [95% CI, 0.40-0.72]; p &lt; 0.001]). The 12-month PFS2 rate was 59.7<br \/>\n      percent in the KEYTRUDA group and 38.5 percent in the chemotherapy<br \/>\n      group; the 18-month PFS2 rate was 51.0 percent in the KEYTRUDA group and<br \/>\n      24.6 percent in the chemotherapy group. The median PFS2 was 18.3 months<br \/>\n      in the KEYTRUDA group (95% CI, 12.7-NE) compared to 8.4 months in the<br \/>\n      chemotherapy group (95% CI, 6.8-9.8).\n    <\/p>\n<p>\n      A safety analysis was not performed for this data set.\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer, which forms in the tissues of the lungs, usually within<br \/>\n      cells lining the air passages, is the leading cause of cancer death<br \/>\n      worldwide. Each year, more people die of lung cancer than die of colon,<br \/>\n      breast and prostate cancers combined. The two main types of lung cancer<br \/>\n      are non-small cell and small cell. NSCLC is the most common type of lung<br \/>\n      cancer, accounting for about 85 percent of all cases. The five-year<br \/>\n      survival rate for patients suffering from highly advanced, metastatic<br \/>\n      (Stage IV) lung cancers is estimated to be two percent.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 500 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single-dose vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b> <b>Indications<br \/>\n      and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA<br \/>\n      (pembrolizumab) is administered at a fixed dose of 200 mg every three<br \/>\n      weeks until disease progression, unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause thyroid disorders, including<br \/>\n      hyperthyroidism, hypothyroidism, and thyroiditis. Hyperthyroidism<br \/>\n      occurred in 96 (3.4%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.8%) and 3 (0.1%) hyperthyroidism. Hypothyroidism occurred in<br \/>\n      237 (8.5%) of 2799 patients receiving KEYTRUDA, including Grade 2 (6.2%)<br \/>\n      and 3 (0.1%) hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis.<br \/>\n      Monitor patients for changes in thyroid function (at the start of<br \/>\n      treatment, periodically during treatment, and as indicated based on<br \/>\n      clinical evaluation) and for clinical signs and symptoms of thyroid<br \/>\n      disorders. Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA (pembrolizumab). Treatment with KEYTRUDA may increase the<br \/>\n      risk of rejection in solid organ transplant recipients. Consider the<br \/>\n      benefit of treatment with KEYTRUDA vs the risk of possible organ<br \/>\n      rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682 patients with metastatic NSCLC. The most common adverse event<br \/>\n      resulting in permanent discontinuation of KEYTRUDA was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA (pembrolizumab) is excreted in human<br \/>\n      milk. Because many drugs are excreted in human milk, instruct women to<br \/>\n      discontinue nursing during treatment with KEYTRUDA and for 4 months<br \/>\n      after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Findex.html&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=03efe3e4445134b6998072f24a515295\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=5c0d08e4c907765ed20c8e6dae13c6e9\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=e5f61e9638f5a74dc62b67ccff9a1d37\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=e4c08f2f6eca5830ca33b195c9477fb5\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=23809af84775fb7090fb2e732f04a754\" rel=\"nofollow\">Instagram<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=75d5b1622275446a355354b0c63b05e1\" rel=\"nofollow\">YouTube<\/a>&nbsp;and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=bf3864f4c159033314f23b87bab65325\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=a3478a24a9d3700742190a9e61473ec9\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n      # # #\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=c360ed847dcce2c32f71fadc957a0055\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51569466&amp;newsitemid=20170605005534&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=2d7a006ef7e2e43d9f64a0690ef05d57\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170605005534r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Teresa Mueller,        908-740-1884<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Longer-Term Findings to Be Presented at 2017 ASCO Annual Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated overall survival (OS) findings from KEYNOTE-024, the phase 3 study evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy compared to platinum-containing chemotherapy in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 (tumor proportion score [TPS] of 50 percent or more). The study included patients with squamous and non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations and demonstrated a reduction in the risk of death by 37 percent for KEYTRUDA compared to chemotherapy based on 19 months of median follow-up (HR, 0.63 [95% CI, 0.46-0.88]; p = 0.003). Additionally, in an exploratory analysis, progression-free survival 2 (PFS2) \u2013 a clinical endpoint used to assess the impact of next-line treatment on disease<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[149,53,64,55,289],"class_list":["post-745531","news_item","type-news_item","status-publish","hentry","tag-asco","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Longer-Term Findings to Be Presented at 2017 ASCO Annual Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated overall survival (OS) findings from KEYNOTE-024, the phase 3 study evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy compared to platinum-containing chemotherapy in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 (tumor proportion score [TPS] of 50 percent or more). The study included patients with squamous and non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations and demonstrated a reduction in the risk of death by 37 percent for KEYTRUDA compared to chemotherapy based on 19 months of median follow-up (HR, 0.63 [95% CI, 0.46-0.88]; p = 0.003). Additionally, in an exploratory analysis, progression-free survival 2 (PFS2) \u2013 a clinical endpoint used to assess the impact of next-line treatment on disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"18 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\\\/\",\"name\":\"Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-06-05T06:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/","og_locale":"en_US","og_type":"article","og_title":"Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1 - Merck.com","og_description":"Longer-Term Findings to Be Presented at 2017 ASCO Annual Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated overall survival (OS) findings from KEYNOTE-024, the phase 3 study evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy compared to platinum-containing chemotherapy in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 (tumor proportion score [TPS] of 50 percent or more). The study included patients with squamous and non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations and demonstrated a reduction in the risk of death by 37 percent for KEYTRUDA compared to chemotherapy based on 19 months of median follow-up (HR, 0.63 [95% CI, 0.46-0.88]; p = 0.003). Additionally, in an exploratory analysis, progression-free survival 2 (PFS2) \u2013 a clinical endpoint used to assess the impact of next-line treatment on disease","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:25+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"18 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/","name":"Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-06-05T06:30:00+00:00","dateModified":"2025-11-07T06:26:25+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-from-keynote-024-show-continued-overall-survival-benefit-of-mercks-keytruda-pembrolizumab-compared-to-chemotherapy-in-the-first-line-treatment-of-patients-with-metastatic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"aaf681fc-e967-475e-910d-385dd55facd2","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Updated-Data-from-KEYNOTE-024-Show-Continued-Overall-Survival-Benefit-of-Mercks-KEYTRUDA-pembrolizumab-Compared-to-Chemotherapy-in-th-AVE9C.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745531\/revisions"}],"predecessor-version":[{"id":3674887,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745531\/revisions\/3674887"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745531"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}